Immuneering Corporation (IMRX)

Immuneering Statistics

Total Valuation

Immuneering has a market cap or net worth of $295.73 million. The enterprise value is $72.08 million.

Market Cap	295.73M
Enterprise Value	72.08M

Important Dates

The last earnings date was Wednesday, November 12, 2025, after market close.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Immuneering has 64.57 million shares outstanding. The number of shares has increased by 20.43% in one year.

Current Share Class	64.57M
Shares Outstanding	64.57M
Shares Change (YoY)	+20.43%
Shares Change (QoQ)	+10.24%
Owned by Insiders (%)	13.73%
Owned by Institutions (%)	40.84%
Float	49.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.28
P/TBV Ratio	1.34
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 24.00, with a Debt / Equity ratio of 0.02.

Current Ratio	24.00
Quick Ratio	23.84
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -43.75% and return on invested capital (ROIC) is -27.30%.

Return on Equity (ROE)	-43.75%
Return on Assets (ROA)	-25.91%
Return on Invested Capital (ROIC)	-27.30%
Return on Capital Employed (ROCE)	-27.72%
Revenue Per Employee	n/a
Profits Per Employee	-$946,915
Employee Count	66
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +141.05% in the last 52 weeks. The beta is 0.47, so Immuneering's price volatility has been lower than the market average.

Beta (5Y)	0.47
52-Week Price Change	+141.05%
50-Day Moving Average	6.35
200-Day Moving Average	4.54
Relative Strength Index (RSI)	38.50
Average Volume (20 Days)	3,191,947

Short Selling Information

The latest short interest is 10.92 million, so 16.92% of the outstanding shares have been sold short.

Short Interest	10.92M
Short Previous Month	7.64M
Short % of Shares Out	16.92%
Short % of Float	22.14%
Short Ratio (days to cover)	8.45

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-64.18M
Pretax Income	-62.50M
Net Income	-62.50M
EBITDA	-63.82M
EBIT	-64.18M
Earnings Per Share (EPS)	-$1.76

Balance Sheet

The company has $227.56 million in cash and $3.92 million in debt, with a net cash position of $223.65 million or $3.46 per share.

Cash & Cash Equivalents	227.56M
Total Debt	3.92M
Net Cash	223.65M
Net Cash Per Share	$3.46
Equity (Book Value)	227.98M
Book Value Per Share	3.59
Working Capital	219.56M

Cash Flow

In the last 12 months, operating cash flow was -$50.01 million and capital expenditures -$27,672, giving a free cash flow of -$50.04 million.

Operating Cash Flow	-50.01M
Capital Expenditures	-27,672
Free Cash Flow	-50.04M
FCF Per Share	-$0.78

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immuneering does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.43%
Shareholder Yield	-20.43%
Earnings Yield	-21.13%
FCF Yield	-16.92%

Analyst Forecast

The average price target for Immuneering is $17.20, which is 275.55% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$17.20
Price Target Difference	275.55%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-8.65%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2